Revolutionary In-Body CAR-T therapy targets autoimmune diseases

NCT ID NCT07413341

Recruiting now Disease control Sponsor: Therorna Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target and destroy faulty B cells that cause the disease. The main goal is to check safety, with a small group of 12 participants, and it is not yet proven to be a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis inclusion body myositis myositis disease Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA ASSOCIATED SYSTEMIC VASCULITIS INFLAMMATORY MYOPATHY SJOGREN'S SYNDROME (SS) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Show contact details

Study contacts

Contact
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Changzheng Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200003, China

Contact Phone: •••-•••-•••• Email: •••••@•••••